Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluate the Pharmacokinetics and Gonadotropin Suppression of Nestorone®-Testosterone (NES/T) Combination Gel in Men

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02432261
Recruitment Status : Completed
First Posted : May 4, 2015
Last Update Posted : May 14, 2018
Sponsor:
Collaborator:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Information provided by (Responsible Party):
Health Decisions

Brief Summary:
This is a prospective, randomized, double-blinded, two-center trial to evaluate the gonadotropin suppressive activity of transdermal treatment with a combined NES/T gel, or T gel alone, for 28 days.

Condition or disease Intervention/treatment Phase
Healthy Drug: Nestorone® /testosterone gel Drug: Testosterone only gel Phase 1

Detailed Description:

A total of 45 subjects will be enrolled and randomized in a 2:1 ratio to one of two treatment groups. A description of each group is as follows:

  • Group 1 (30 subjects): 5.0 mL of the 1.62% combined gel (containing 8.3 mg NES + 62.5 mg T) applied each day on the arms and shoulders
  • Group 2 (15 subjects): 4.4 mL of the 1.62% AndrogelTM (containing 62.7 mg T) applied each day to the arms and shoulders

The total duration of treatment will be 28 days followed by a 72 hour sampling period to assess half-life and a recovery period of at least 28 days, at which point the subjects will return to the clinic for an end of study visit.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 44 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Other
Official Title: A Randomized, Two Center, Double-Blind Trial to Evaluate the Pharmacokinetics and Gonadotropin Suppression of Nestorone®-Testosterone (NES/T) Combination Gel in Healthy Men
Study Start Date : April 2015
Actual Primary Completion Date : March 2016
Actual Study Completion Date : March 2016

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Group 1
5.0 mL of the 1.62% Nestorone® /testosterone gel (containing 8.3 mg NES + 62.5 mg T) applied each day on the arms and shoulders
Drug: Nestorone® /testosterone gel
Nestorone® /testosterone combined gel

Experimental: Group 2
4.4 mL of the 1.62% Testosterone only gel (AndrogelTM) (containing 62.7 mg T) applied each day to the arms and shoulders
Drug: Testosterone only gel
Testosterone only gel
Other Name: Androgel




Primary Outcome Measures :
  1. Gonadotropin Suppression [ Time Frame: 4 weeks ]
    To quantify the gonadotropin suppressive activity of 4 weeks daily therapy of a combination transdermal gel containing 8.3 mg Nestorone® (NES) gel and 62.5 mg (1.62%) testosterone (T) gel, and of T gel (1.62%) alone. Specifically, the proportion (and 95% CI) of men who suppress both gonadotropins (luteinizing hormone [LH] and follicle-stimulating hormone [FSH]) to ≤ 1 IU/L in each group, will be quantified.


Secondary Outcome Measures :
  1. Gonadotropin and follicle-stimulating hormone suppression [ Time Frame: 4 weeks ]
    • To quantify the proportion (and 95% CI) of men who suppress both gonadotropins (luteinizing hormone [LH] and follicle-stimulating hormone [FSH]) to the detection limit of the assay in each group.

  2. Change in LH and FSH concentrations [ Time Frame: 4 weeks ]
    • To quantify the median percent change from baseline to week 4 and interquartile range for serum gonadotropins (LH and FSH) concentrations for each treatment group.

  3. Acceptability and Satisfaction as measured by the Contraceptive Gel Acceptability and Satisfaction Questionnaire by comparing T and NES serum concentrations. [ Time Frame: Multiple times on Day 1 ]
    Serum hormone samples for Nes and T will be drawn before gel application on days 1, 7, 11, 14, 21, 25 and 28.

  4. Acceptability and Satisfaction as measured by the Contraceptive Gel Acceptability and Satisfaction Questionnaire by comparing T and NES serum concentrations. [ Time Frame: 4 weeks ]
    • To compare T and NES concentrations at week 3 and at week 4 using the combined NES/T gel to prior serum concentrations obtained with individual T and NES gel applications at week 3 (CCN005), and week 4 (CCN007), respectively (historical comparison).

  5. A composite safety of the combined gel determined by outcomes of CBC, chemistry, AEs, vitals, physical changes, and Psychosexual & Patient Health Questionnaires which will all be measured at multiple time points throughout the study. [ Time Frame: 4 weeks ]

    General composite safety as measured various times during the study by CBC, chemistry, AEs, vital signs, general pre- and post-treatment physical exams and PSA levels.

    In addition to the above composite measures, another safety outcomes to be included in the overall composite safety review will include changes in mood based on Patient Health Questionnaire and changes in sexual function based on Psychosexual Safety outcomes, both measured by a questionnaire.


  6. Assessing sexual function by compare gonadotropin suppressive activity of T and NES against T alone through the Psychosexual Daily questionnaire. [ Time Frame: 4 weeks ]
    LH, FSH, T levels in serum will be assayed at screening plus treatment days 1, 7, 11, 14, 21, 25, 28, 30, 31 and at study exit.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Male volunteers in good health as confirmed by physical examination, medical history, and clinical laboratory tests of blood and urine at the time of screening;
  2. 18 to 50 years of age;
  3. BMI < 33 calculated as weight in Kg/(height in cm)2;
  4. No history of hormonal therapy use in the last six months prior to the first screening visit;
  5. Subject will agree to use a recognized effective method of contraception with his partner (i.e. at a minimum, condom for the male partner and an effective contraception for the female partner) during the course of the study treatment and recovery phase;
  6. In the opinion of the investigator, subject is able to comply with the protocol, understand and sign an informed consent and HIPAA form;
  7. Does not meet any of the exclusion criteria.
  8. Sperm concentration ≥ 15 million sperm per milliliter ejaculate.

Exclusion Criteria:

  1. Men participating in another clinical trial involving an investigational drug within the last 30 days prior to the first screening visit;
  2. Men not living in the catchment's area of the clinic or within a reasonable distance from the site;
  3. Clinically significant abnormal physical findings at screening;
  4. Elevated PSA (levels ≥ 4 ng/mL), according to local laboratory normal values;
  5. Abnormal serum chemistry values, according to local laboratory normal values that indicate liver or kidney dysfunction or that may be considered clinically significant;
  6. Use of androgens or body building substances within 6 months before first screening visit;
  7. Diastolic blood pressure (DBP) > 80 and/or Systolic (SBP) > 130 mm Hg;
  8. EKG abnormal and clinically significant and QTC level longer than 450msec;
  9. History of hypertension, including hypertension controlled with treatment;
  10. Known history of primary testicular disease or disorders of the hypothalamic-pituitary axis;
  11. Known hypersensitivity to progestins or androgen;
  12. Family or personal history of venous thromboembolism;
  13. Benign or malignant liver tumors; active liver disease;
  14. Known history of reproductive dysfunction including vasectomy or infertility;
  15. Known history of cardiovascular, renal, hepatic or prostatic disease;
  16. A serious systemic disease such as diabetes mellitus or morbid obesity (body weight greater than 120% of ideal body weight or BMI limitation as above);
  17. Known or suspected alcoholism or drug abuse that may affect metabolism/transformation of steroid hormones and study treatment compliance;
  18. Known dermatitis or severe skin disorder;
  19. Moderate or severe depression as determined by PHQ-9 score >15;
  20. Partner is known to be pregnant;
  21. Known or suspected breast or prostate cancer;
  22. Allergic to any ingredient in testosterone/nestorone gel, including alcohol;
  23. Known history of untreated sleep apnea;
  24. International Prostate Symptom Score (IPSS) greater than or equal to 15.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02432261


Locations
Layout table for location information
United States, California
LA Biomedical Research Institute
Torrance, California, United States, 90502
United States, Washington
University of Washington
Seattle, Washington, United States, 98195
Sponsors and Collaborators
Health Decisions
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Investigators
Layout table for investigator information
Principal Investigator: Christina Wang, MD Research Site
Principal Investigator: William Bremner, MD Research Site
Layout table for additonal information
Responsible Party: Health Decisions
ClinicalTrials.gov Identifier: NCT02432261    
Other Study ID Numbers: CCN005A
First Posted: May 4, 2015    Key Record Dates
Last Update Posted: May 14, 2018
Last Verified: May 2018
Keywords provided by Health Decisions:
spermatogenesis
androgen
male contraception
Additional relevant MeSH terms:
Layout table for MeSH terms
ST 1435
Contraceptive Agents, Female
Contraceptive Agents
Methyltestosterone
Testosterone
Testosterone undecanoate
Testosterone enanthate
Testosterone 17 beta-cypionate
Androgens
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Anabolic Agents
Reproductive Control Agents